Lv2
140 积分 2023-10-08 加入
A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer
20天前
已完结
Epidermal growth factor receptor inhibition strategies in oncology
25天前
已完结
Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix
25天前
已完结
Update on novel therapeutic agents for cervical cancer
25天前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial
4个月前
已完结
99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy
5个月前
已完结
Strategic Approaches in Management of Early-Stage Cervical Cancer: A Comprehensive Editorial
7个月前
已完结
Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone – Additional data from a phase 3 trial
7个月前
已完结
Incisor Degeneration in Rats Induced by Vascular Endothelial Growth Factor/Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibition
8个月前
已完结
皖公网安备34019202002308
